Literature DB >> 32759362

Cross-dressing of CD8α+ Dendritic Cells with Antigens from Live Mouse Tumor Cells Is a Major Mechanism of Cross-priming.

Alok Das Mohapatra1, Isaac Tirrell1, Alexandre P Bénéchet1, Shashmita Pattnayak1, Kamal M Khanna1, Pramod K Srivastava2.   

Abstract

Live cells are the most abundant sources of antigen in a tumor-bearing host. Here, we used live tumor cells as source of antigens to investigate the mechanism underlying their immunogenicity in murine tumor models. The live tumor cells were significantly more immunogenic than irradiated or apoptotic tumor cells. We examined the interaction of live and apoptotic tumor cells with major subsets of antigen-presenting cells, i.e., CD8α+ dendritic cells (DC), CD8α- DCs, plasmacytoid DCs, and CD169+ macrophages at skin draining lymph nodes. The CD8α+ DCs captured cell-associated antigens from both live and apoptotic tumor cells, whereas CD169+ macrophages picked up cell-associated antigens mostly from apoptotic tumor cells. Trogocytosis and cross-dressing of membrane-associated antigenic material from live tumor cells to CD8α+ DCs was the primary mechanism for cross-priming of tumor antigens upon immunization with live cells. Phagocytosis of apoptotic tumor cells was the primary mechanism for cross-priming of tumor antigens upon immunization with apoptotic or irradiated cells. These findings clarify the mechanism of cross-priming of cancer antigens by DCs, allowing for a greater understanding of antitumor immune responses. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32759362     DOI: 10.1158/2326-6066.CIR-20-0248

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  8 in total

Review 1.  Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion.

Authors:  Suchit Jhunjhunwala; Christian Hammer; Lélia Delamarre
Journal:  Nat Rev Cancer       Date:  2021-03-09       Impact factor: 60.716

2.  CD169-positive macrophages enhance abscopal effect of radiofrequency ablation therapy in liver cancer.

Authors:  Xiaojia Song; Na Li; Yuan Liu; Zehua Wang; Tixiao Wang; Siyu Tan; Chunyang Li; Chunhong Qiu; Lifen Gao; Kenichi Asano; Masato Tanaka; Xiaohong Liang; Xinyong Liu; Chunhong Ma
Journal:  Transl Oncol       Date:  2021-12-06       Impact factor: 4.243

3.  Chaperone-Mediated Autophagy Ablation in Pericytes Reveals New Glioblastoma Prognostic Markers and Efficient Treatment Against Tumor Progression.

Authors:  María Luisa Molina; David García-Bernal; María Dolores Salinas; Gonzalo Rubio; Pedro Aparicio; José M Moraleda; Salvador Martínez; Rut Valdor
Journal:  Front Cell Dev Biol       Date:  2022-03-18

Review 4.  Antigen transfer and its effect on vaccine-induced immune amplification and tolerance.

Authors:  Yingying Shi; Yichao Lu; Jian You
Journal:  Theranostics       Date:  2022-08-01       Impact factor: 11.600

5.  Trogocytosis in innate immunity to cancer is an intimate relationship with unexpected outcomes.

Authors:  Fabrizio Mattei; Sara Andreone; Francesca Spadaro; Francesco Noto; Antonella Tinari; Mario Falchi; Silvia Piconese; Claudia Afferni; Giovanna Schiavoni
Journal:  iScience       Date:  2022-09-12

6.  Dendritic cell cross-dressing and tumor immunity.

Authors:  Amaia Martinez-Usatorre; Michele De Palma
Journal:  EMBO Mol Med       Date:  2022-08-12       Impact factor: 14.260

Review 7.  Shaping of T Cell Functions by Trogocytosis.

Authors:  Masafumi Nakayama; Arisa Hori; Saori Toyoura; Shin-Ichiro Yamaguchi
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

8.  P2X7 receptor is essential for cross-dressing of bone marrow-derived dendritic cells.

Authors:  Carlos Barrera-Avalos; Pedro Briceño; Daniel Valdés; Mónica Imarai; Elías Leiva-Salcedo; Leonel E Rojo; Luis A Milla; Juan Pablo Huidobro-Toro; Claudia Robles-Planells; Alejandro Escobar; Francesco Di Virgilio; Gabriel Morón; Daniela Sauma; Claudio Acuña-Castillo
Journal:  iScience       Date:  2021-11-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.